- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-BRAF monoclonal antibody
Pre-made anti-BRAF monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to BRAF/BRAF products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T99089-Ab-1/ GM-Tg-hg-T99089-Ab-2 | Anti-Human BRAF monoclonal antibody | Human |
| GM-Tg-rg-T99089-Ab-1/ GM-Tg-rg-T99089-Ab-2 | Anti-Rat BRAF monoclonal antibody | Rat |
| GM-Tg-mg-T99089-Ab-1/ GM-Tg-mg-T99089-Ab-2 | Anti-Mouse BRAF monoclonal antibody | Mouse |
| GM-Tg-cynog-T99089-Ab-1/ GM-Tg-cynog-T99089-Ab-2 | Anti-Cynomolgus/ Rhesus macaque BRAF monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T99089-Ab-1/ GM-Tg-felg-T99089-Ab-2 | Anti-Feline BRAF monoclonal antibody | Feline |
| GM-Tg-cang-T99089-Ab-1/ GM-Tg-cang-T99089-Ab-2 | Anti-Canine BRAF monoclonal antibody | Canine |
| GM-Tg-bovg-T99089-Ab-1/ GM-Tg-bovg-T99089-Ab-2 | Anti-Bovine BRAF monoclonal antibody | Bovine |
| GM-Tg-equg-T99089-Ab-1/ GM-Tg-equg-T99089-Ab-2 | Anti-Equine BRAF monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T99089-Ab-1/ GM-Tg-hg-T99089-Ab-2; GM-Tg-rg-T99089-Ab-1/ GM-Tg-rg-T99089-Ab-2; GM-Tg-mg-T99089-Ab-1/ GM-Tg-mg-T99089-Ab-2; GM-Tg-cynog-T99089-Ab-1/ GM-Tg-cynog-T99089-Ab-2; GM-Tg-felg-T99089-Ab-1/ GM-Tg-felg-T99089-Ab-2; GM-Tg-cang-T99089-Ab-1/ GM-Tg-cang-T99089-Ab-2; GM-Tg-bovg-T99089-Ab-1/ GM-Tg-bovg-T99089-Ab-2; GM-Tg-equg-T99089-Ab-1/ GM-Tg-equg-T99089-Ab-2 |
| Products Name | Anti-BRAF monoclonal antibody |
| Format | mab |
| Target Name | BRAF |
| Protein Sub-location | Introcelluar Protein |
| Category of antibody | Therapeutics Target antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
| Tag | Fc |
| Products description | Pre-made anti-BRAF monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-T99089-Ag-1 | Recombinant multi-species BRAF/ B-RAF1/ B-raf1 protein |
| ORF Viral Vector | pGMLP001460 | human BRAF Lentivirus plasmid |
| ORF Viral Vector | pGMLV000876 | human BRAF Lentivirus plasmid |
| ORF Viral Vector | vGMLV000876 | human BRAF Lentivirus particle |
| ORF Viral Vector | pGMLV000626 | human BRAF Lentivirus plasmid |
| ORF Viral Vector | vGMLP001460 | human BRAF Lentivirus particle |
| ORF Viral Vector | vGMLV000626 | human BRAF Lentivirus particle |
Target information
| Target ID | GM-T99089 |
| Target Name | BRAF |
| Gene ID | 673,109880,114486,693554,475526,101092346,536051,100065760 |
| Gene Symbol and Synonyms | 9930012E13Rik,B-raf,B-RAF1,BRAF,BRAF-1,Braf-2,BRAF1,Braf2,C230098H17,D6Ertd631e,NS7,RAFB1 |
| Uniprot Accession | P15056 |
| Uniprot Entry Name | BRAF_HUMAN |
| Protein Sub-location | Introcelluar Protein |
| Category | Therapeutics Target |
| Disease | Non-Small Cell Lung Cancer, Colorectal Cancer, Melanoma Cancer |
| Gene Ensembl | ENSG00000157764 |
| Target Classification | Kinase |
The target: BRAF, gene name: BRAF, also named as B-RAF1, B-raf1, NS7, RAFB1, BRAF. This gene encodes a protein belonging to the RAF family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene, most commonly the V600E mutation, are the most frequently identified cancer-causing mutations in melanoma, and have been identified in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of lung. Mutations in this gene are also associated with cardiofaciocutaneous, Noonan, and Costello syndromes, which exhibit overlapping phenotypes. A pseudogene of this gene has been identified on the X chromosome. [provided by RefSeq, Aug 2017].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
